Angelica Lindén Hirschberg still remembers the first woman in the Stockholm trial who, after years of silence from her ovaries, produced mature follicles capable of yielding viable eggs. She was one of 10 women with autoimmune premature ovarian insufficiency (POI) who underwent an experimental treatment at Karolinska Institutet—and one of three who would eventually cradle a newborn after being told motherhood might never be possible. For women affected by POI, a condition that halts ovarian function before age 40 and impacts over 3% of women globally, this small but groundbreaking study offers a sliver of hope where little existed before.
Premature ovarian insufficiency has long been considered a permanent barrier to biological motherhood, especially when driven by autoimmune mechanisms. But Lindén Hirschberg and her team questioned whether the immune system’s attack on ovarian tissue might be temporarily silenced—enough to awaken dormant egg reserves. They focused on rituximab, a well-established immunotherapy drug used for autoimmune diseases and certain cancers. The pilot trial enrolled 12 women aged 18 to 35 with confirmed autoimmune POI; two withdrew before treatment began.
Each participant underwent ovarian stimulation before and again four to six months after receiving rituximab. Before treatment, none responded—no follicles matured, no eggs could be retrieved. After immunotherapy, everything changed for more than half: 6 out of 10 women developed mature follicles. In five of those, eggs were successfully frozen or fertilized. Three women proceeded to embryo transfer—conducted at least one year post-treatment for safety—and all three gave birth to healthy babies. Notably, all responders also had autoimmune Addison’s disease, suggesting a potential biomarker for treatment success.
One serious adverse event occurred, linked not to rituximab but to the hormonal stimulation protocol—a known risk in fertility treatments. The study, published in NEJM Evidence, is a proof-of-concept without a control group, so conclusions are cautious. Still, the implications ripple beyond the 10 participants. For the first time, researchers have shown that fertility restoration in certain forms of POI isn’t just theoretical—it’s possible.
“This is a first step,” says Lindén Hirschberg, whose team has already launched a larger, randomized trial to validate these findings. If confirmed, this approach could redefine treatment for a subset of women with autoimmune infertility. Science is learning that sometimes, the body isn’t broken—just silenced. And with the right key, it can speak again.